Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

1,318

US Approved Rx

1,050

Possibly Marketed Outside US

359

Designated

349

US Previously Marketed

149

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA

71

Vascular endothelial growth factor receptor 2

28

Stem cell growth factor receptor

24

Histone deacetylase 1

20

Platelet-derived growth factor receptor beta

19

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

992

Phase II

178

Phase III

153

Phase I

42

Not Provided

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

1,936

1921

73

2020

49

2018

46

2023

40

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Breast cancer

71

Non-small cell lung cancer

65

Multiple myeloma

56

Unknown

52

Ovarian cancer

47

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1,132

Palliative

170

Curative

158

Preventing

133

Diagnostic

59

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

424

CNS Active

332

CNS Non-penetrant

145

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

32

Novartis

28

Eli Lilly

18

Merck

17

Bayer

16

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2,264

Protein

724

Structurally Diverse

103

Concept

82

Mixture

53

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Monoclonal antibodies(-mab)

24

Tyrosine-kinase inhibitors(-tinib)

13

Chemical substance(-ine)

7

Peptides and glycopeptides(-tide)

7

Gene Therapy vectors(-vec)

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

3,286

FDA ORPHAN DRUG

3,058

CAS

3,029

SMS_ID

2,772

NCI_THESAURUS

2,607

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

256

MONOCLONAL ANTIBODY CONJUGATE

43

BISPECIFIC ANTIBODY

33

PEPTIDE

32

ENZYME

31

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

237

ALIMENTARY TRACT AND METABOLISM

128

ANTIINFECTIVES FOR SYSTEMIC USE

87

NERVOUS SYSTEM

81

CARDIOVASCULAR SYSTEM

76

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

160

OPHTHALMOLOGICALS

51

IMMUNOSUPPRESSANTS

46

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

36

ALL OTHER THERAPEUTIC PRODUCTS

34

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

120

IMMUNOSUPPRESSANTS

46

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

36

ALL OTHER THERAPEUTIC PRODUCTS

33

DIRECT ACTING ANTIVIRALS

33

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antineoplastic agents

42

Protein kinase inhibitors

40

Enzymes

29

Monoclonal antibodies

28

Selective immunosuppressants

20

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2,576

Salts, Hydrates, Esters, etc.

710

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG" in comments (approximate match)

Showing 3321 - 3321 of 3,321 results

First page
Previous page
333
Next page disabled
Next page disabled

VINCRISTINE SULFATE LIPOSOME

T5IRO3534A

Status:

Other

Class:

CONCEPT

Showing 3321 - 3321 of 3,321 results

First page
Previous page
333
Next page disabled
Next page disabled

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1